What is the 13F Pro Quality Score for CLGN?

13F Pro ranks CollPlant Biotechnologies Ltd (CLGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLGN's current score at https://13fpro.ai/company/CLGN (free sign-up required for the full ranking).

Which hedge funds own the most CLGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CLGN include PINNACLE ASSOCIATES LTD, VILLERE ST DENIS J & CO, BROWN ADVISORY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CLGN as soon as new 13F filings post.

Where does 13F Pro source CLGN data?

All CollPlant Biotechnologies Ltd fundamentals and ownership data come directly from SEC EDGAR. CollPlant Biotechnologies Ltd files with the SEC under CIK 1631487. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLGN in?

CollPlant Biotechnologies Ltd (CLGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLGN research updated on 13F Pro?

CLGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CollPlant Biotechnologies Ltd(CLGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1631487 CLGN stock profile & AI dashboard →

13F Pro Quality Score

15.6/100

Rank #2,852 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CLGN Scores 16/100

exact factor attribution · 2026-09-11

CLGN's composite is driven by institutional flow, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+1.9 pts

87th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.1 pts

9th pct

Earnings quality

-2.4 pts

26th pct

Capital efficiency

-3.8 pts

12th pct

Profitability

-5.0 pts

16th pct

Scale

-6.3 pts

8th pct

Free cash flow

-6.5 pts

7th pct

Revenue growth

-9.2 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CLGN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CollPlant Biotechnologies Ltd (CLGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLGN at 15.6/100 on a 32-signal composite quality model, placing it at rank #2,852 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), CollPlant Biotechnologies Ltd reports quarterly revenue of $2.4M, net income of $-11.5M, free cash flow of $-9.4M. Top institutional holders of CLGN by reported 13-F value include PINNACLE ASSOCIATES LTD, VILLERE ST DENIS J, BROWN ADVISORY, based on the most recent SEC filings. CLGN trades on the Nasdaq exchange and files with the SEC under CIK 1631487. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CollPlant Biotechnologies Ltd directly from SEC EDGAR.

Revenue

FY 2025

$2.4M

Net Income

FY 2025

$-11.5M

Free Cash Flow

FY 2025

$-9.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+360.4% YoY

$2.4MFY 2025

FY22 $299.0KFY23 $11.0MFY24 $515.0KFY25 $2.4M

Net Income

+30.8% YoY

$-11.5MFY 2025

FY22 $-16.9MFY23 $-7.0MFY24 $-16.6MFY25 $-11.5M

Operating Income

+33.4% YoY

$-11.5MFY 2025

FY22 $-17.1MFY23 $-7.5MFY24 $-17.3MFY25 $-11.5M

EPS (Diluted)

+35.2% YoY

$-0.94FY 2025

FY22 $-1.53FY23 $-0.62FY24 $-1.45FY25 $-0.94

Total Assets

-42.4% YoY

$10.8MFY 2025

FY22 $37.8MFY23 $34.1MFY24 $18.7MFY25 $10.8M

Total Debt

—FY 2025

FY22 $321.0KFY23 —FY24 —FY25 —

Op. Cash Flow

+33.2% YoY

$-9.4MFY 2025

FY22 $-13.7MFY23 $-2.8MFY24 $-14.1MFY25 $-9.4M

Free Cash Flow

+35.2% YoY

$-9.4MFY 2025

FY22 $-15.0MFY23 $-3.7MFY24 $-14.6MFY25 $-9.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.4M +360.4%	$515.0K -95.3%	$11.0M +3565.2%	$299.0K -98.1%	$15.6M +154.9%	$6.1M
Net Income	$-11.5M +30.8%	$-16.6M -136.6%	$-7.0M +58.5%	$-16.9M -7241.4%	$237.0K +104.1%	$-5.8M
Operating Income	$-11.5M +33.4%	$-17.3M -129.6%	$-7.5M +56.1%	$-17.1M -26403.1%	$65.0K +101.2%	$-5.6M
EPS (Diluted)	$-0.94 +35.2%	$-1.45 -133.9%	$-0.62 +59.5%	$-1.53 -7750.0%	$0.02 +102.4%	$-0.84
Total Assets	$10.8M -42.4%	$18.7M -45.2%	$34.1M -9.6%	$37.8M -26.3%	$51.2M +372.5%	$10.8M
Total Debt	—	—	—	$321.0K +28.9%	$249.0K +2163.6%	$11.0K
Operating Cash Flow	$-9.4M +33.2%	$-14.1M -410.1%	$-2.8M +79.8%	$-13.7M -647.7%	$2.5M +156.2%	$-4.5M
Free Cash Flow	$-9.4M +35.2%	$-14.6M -292.1%	$-3.7M +75.2%	$-15.0M -1495.3%	$1.1M +122.0%	$-4.9M

Get alerted when CLGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CollPlant Biotechnologies Ltd including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLGN

PINNACLE ASSOCIATES LTD
$255.3K731,663 sh
VILLERE ST DENIS J & CO LLC
$211.6K606,400 sh
BROWN ADVISORY INC
$36.5K104,731 sh
RENAISSANCE TECHNOLOGIES LLC
$21.5K61,500 sh
Pathstone Holdings, LLC
$19.9K57,000 sh
CITADEL ADVISORS LLC
$18.7K53,700 sh
Legacy Wealth Managment, LLC/ID
$8.1K23,179 sh
WATERS PARKERSON & CO., LLC
$4.6K13,250 sh
XTX Topco Ltd
$4.6K13,081 sh
FNY Investment Advisers, LLC
$1.0K5,250 sh

Fund	Value	Shares
PINNACLE ASSOCIATES LTD	$255.3K	731,663
VILLERE ST DENIS J & CO LLC	$211.6K	606,400
BROWN ADVISORY INC	$36.5K	104,731
RENAISSANCE TECHNOLOGIES LLC	$21.5K	61,500
Pathstone Holdings, LLC	$19.9K	57,000
CITADEL ADVISORS LLC	$18.7K	53,700
Legacy Wealth Managment, LLC/ID	$8.1K	23,179
WATERS PARKERSON & CO., LLC	$4.6K	13,250
XTX Topco Ltd	$4.6K	13,081
FNY Investment Advisers, LLC	$1.0K	5,250

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLGN on your watchlist

Track score changes the day CollPlant Biotechnologies Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLGN a good stock to buy?

13F Pro's AI-powered analysis of CollPlant Biotechnologies Ltd (CLGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLGN are available on the CLGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CLGN is classified as a small company.

Which hedge funds own CLGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CollPlant Biotechnologies Ltd's investment landscape.